Nitto Denko Avecia, a CMO, said it will open its expanded oligonucleotide API manufacturing facility next month in Milford, Massachusetts. The maker of oligonucleotides, which are DNA or RNA molecules used in a variety of applications in genetic testing, research, and forensics, said it expanded the plant by 20,000 square feet for manufacturing and office space.
Avecia, a pharmaceutical manufacturer in Milford, says it is building what will become the largest manufacturing site in the world for a specialized drug ingredient called oligonucleotide. The expansion, which will add 20,000 square feet of space, will more than double the Milford site's total capacity, the company said in an announcement Thursday.
July 13, 2017 /PRNewswire/ -- Nitto Denko Avecia Inc. (Avecia) announced today the opening of its new oligonucleotide API (active pharmaceutical ingredients) manufacturing facility in The opening will commence with a ribbon cutting ceremony in August 2017 onsite at the facility.